Organoid Cultures Derived from Patients with Advanced Prostate Cancer

OrganoidCulturesDerivedfromPatientswithAdvancedProstateCancer
DongGao,1,13IanVela,1,2,13AndreaSboner,3,4,8,13PhillipJ.Iaquinta,1,13WouterR.Karthaus,5AnuradhaGopalan,6CatherineDowling,1,2JacklineN.Wanjala,1EvaA.Undvall,7VivekK.Arora,1,11JohnWongvipat,1MyriamKossai,8SinanRamazanoglu,3,8LuendreoP.Barboza,1WeiDi,1ZhenCao,1QiFanZhang,1InnaSirota,1LeiliRan,1
TheresaY.MacDonald,8HimishaBeltran,4,10Juan-MiguelMosquera,4,8KarimA.Touijer,2PeterT.Scardino,2VincentP.Laudone,2KristenR.Curtis,11DanaE.Rathkopf,10,11MichaelJ.Morris,10,11DanielC.Danila,10,11
SusanF.Slovin,10,11StephenB.Solomon,9JamesA.Eastham,2PingChi,1,10,11BrettCarver,1,2MarkA.Rubin,4,8HowardI.Scher,10,11HansClevers,5CharlesL.Sawyers,1,12,*andYuChen1,10,11,*
OncologyandPathogenesisProgram,MemorialSloanKetteringCancerCenter,NewYork,NY10065,USAService,DepartmentofSurgery,MemorialSloanKetteringCancerCenter,NewYork,NY10065,USA
3InstituteforComputationalBiomedicine,WeillCornellMedicalCollege,NewYork,NY10065,USA
4InstituteforPrecisionMedicineofWeillCornellMedicalCollegeandNewYork-PresbyterianHospital,NewYork,NY10065,USA5HubrechtInstitute,RoyalNetherlandsAcademyofArtsandSciencesandUniversityMedicalCenterUtrecht,3584CT,Utrecht,TheNetherlands
6DepartmentofPathology,MemorialSloanKetteringCancerCenter,NewYork,NY10065,USA7LaboratoryMedicine,MemorialSloanKetteringCancerCenter,NewYork,NY10065,USA
8DepartmentofPathologyandLaboratoryMedicine,WeillCornellMedicalCollegeandNewYork-PresbyterianHospital,NewYork,NY10065,USA
9DepartmentofRadiology,MemorialSloanKetteringCancerCenter,NewYork,NY10065,USA
10DepartmentofMedicine,WeillCornellMedicalCollegeandNewYork-PresbyterianHospital,NewYork,NY10065,USA11DepartmentofMedicine,MemorialSloanKetteringCancerCenter,NewYork,NY10065,USA12HowardHughesMedicalInstitute,ChevyChase,MD20815,USA13Co- rstauthors
*Correspondence:cheny1@mskcc.org(Y.C.),sawyersc@mskcc.org(C.L.S.)doc.guandang.net
2Urology1Human
SUMMARYINTRODUCTION
Thediscoveryofmolecularbiomarkersofdrugsensitivityisparamountfortheprecisiontreatmentofcancerpatients.Asexempli edbyge tinibinnon-small-celllungcancer,manydrugscanleadtoextraordinaryresponsesinsmallsubsetsofpatients,which,whenleftunidenti ed,resultinnegativeclinicaltrials(Thatcheretal.,2005).Invitrocelllines,withthecapacityforunlimitedgrowth,amenabilitytohigh-throughputscreening,andinvivotestingasxenografts,havebeenanimportantresourceintheidenti cationofpredictorsofresponseandresis-tancemechanisms(Drukeretal.,1996;Solitetal.,2006).Large-scalescreensofcancercelllinepanelsthatintegrategenomicpro leswithsensitivitytoalargenumberofcompoundscanidentifydrugsactiveinspeci cgeneticcontextsthatmightotherwisebemissed(Barretinaetal.,2012;Garnettetal.,2012).Earlyresultsfromthesestudiessuggestthatgeneticalter-ationsandcelllineageareimportantdeterminantsofdrugsensi-tivity.Therefore,alargenumberofcelllinesarerequiredtostudyeachspeci clineage.
ProstatecanceristhemostcommonmalignancyandthesecondmostcommoncauseofcancerdeathinWesternmen.Despiteitsprevalence,prostatecancerhasprovenverydif culttopropagateinvitroandishighlyunderrepresentedwithonlysevencelllinesamong 1,000cancercelllinesinpublicrepos-itories(Horoszewiczetal.,1983;Kaighnetal.,1978;Korenchuketal.,2001;Mertzetal.,2007;Navoneetal.,1997;Sramkoski
Cell159,1–12,September25,2014ª2014ElsevierInc.1
Thelackofinvitroprostatecancermodelsthatrecapitulatethediversityofhumanprostatecancerhashamperedprogressinunderstandingdiseasepathogenesisandtherapyresponse.Usinga3Dorganoidsystem,wereportsuccessinlong-termcultureofprostatecancerfrombiopsyspec-imensandcirculatingtumorcells.The rstsevenfullycharacterizedorganoidlinesrecapitulatethemoleculardiversityofprostatecancersub-types,includingTMPRSS2-ERGfusion,SPOPmu-tation,SPINK1overexpression,andCHD1loss.Whole-exomesequencingshowsalowmutationalburden,consistentwithgenomicsstudies,butwithmutationsinFOXA1andPIK3R1,aswellasinDNArepairandchromatinmodi erpathwaysthathavebeenreportedinadvanceddisease.Lossofp53andRBtumorsuppressorpathwayfunctionarethemostcommonfeaturesharedacrosstheorganoidlines.Themethodologydes-cribedhereshouldenablethegenerationofalargerepertoireofpatient-derivedprostatecancerlinesamenabletogeneticandpharmacologicstudies.
from patients with advanced prostate, bladder, or breast cancer as well as...Regardless of whether the peptidome is derived from the tissue/microenvironment...
[6], advanced melanoma [11], prostate cancer [...from healthy donors and from patients with chronic...In DC cultures of four healthy donors, Freezing ...
热门文档